Form 4: Charles River Labs Exec Transfers Shares to Trust

Birgit Girshick, CEO of Charles River Laboratories, transferred 3,386 shares to a revocable trust she controls.

Summary

• Birgit Girshick, Chief Executive Officer of Charles River Laboratories International, Inc., reported a transaction on June 5, 2026.
• The transaction involved the transfer of 3,386 shares of common stock.
• These shares were transferred from direct ownership to a revocable trust controlled by Ms. Girshick.
• This transfer is considered an exempt transaction under Rule 16a-13.
• Following the transaction, Ms. Girshick directly owns 36,013 shares and indirectly owns 43,803 shares through the trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It reports a routine transfer of shares to a trust by an executive, which is a common personal financial planning activity and does not provide insight into the company's performance or future prospects.

Positives

• The transfer of shares to a revocable trust is a common estate planning or asset management strategy.
• The transaction was executed under a Rule 10b5-1(c) plan, suggesting it was pre-planned and not based on insider information.
• Ms. Girshick continues to hold a significant number of shares, indicating continued beneficial ownership and alignment with the company.

Negatives

• No direct financial performance metrics or operational updates are provided in this filing, as it is a Form 4 reporting a change in beneficial ownership.
• The filing does not provide details on the specific reasons for the transfer beyond it being to a revocable trust.

Risks

• While not explicitly stated as a risk in this filing, any significant changes in executive share ownership could be perceived by the market as a signal, though this transfer is to a trust controlled by the executive.
• The filing does not discuss any external risks or challenges faced by the company.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction. It solely reports a change in beneficial ownership.

Management Comments

• The filing includes a signature from Birgit Girshick, indicating her direct involvement in the reported transaction.
• The explanation of responses clarifies that the transfer was made pursuant to Rule 16a-13 of the Securities Exchange Act of 1934.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine for executives and directors to report changes in their holdings. Such transfers to trusts are common for estate planning and do not inherently signal a change in the executive's confidence in the company, especially when the trust is controlled by the reporting person.

Related Party Transactions

• The transfer of 3,386 shares from Birgit Girshick to a revocable trust controlled by her is a related party transaction, as the trust is controlled by the reporting person.

Stakeholder Impact

• Shareholders: No immediate impact is expected as the shares remain beneficially owned by the reporting person. The transfer is a change in the form of ownership, not a sale.
• Employees: No direct impact is anticipated.
• Creditors: No impact is expected.
• Customers: No impact is expected.

Next Steps

• No specific next steps are outlined in this filing beyond the completion of the reported share transfer.

Key Dates

Keywords

Form 4, SEC Filing, Charles River Laboratories, Birgit Girshick, Beneficial Ownership, Stock Transfer, Revocable Trust, Insider Transaction, Rule 16a-13, Executive Compensation